-
Pierre Fabre Partners with RedRidge Bio on BPA Drug Development for Oncology and Dermatology
•
France-based Pierre Fabre Laboratories announced an exclusive R&D collaboration and license agreement with Switzerland-headquartered RedRidge Bio AG. The partnership focuses on discovering and developing biparatopic antibody (BPA) drug candidates against multiple targets, with therapeutic applications in precision oncology, dermatology, and rare diseases. Collaboration DetailsUnder the agreement, RedRidge Bio will be…
